Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer’s disease

Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer’s disease

ObjectiveTo systematically evaluate the efficacy and safety of anti-Aβ monoclonal antibodies (Lecanemab/Donanemab) in the treatment of early Alzheimer’s disease (AD) and to provide evidence for rational clinical use.MethodsWe searched databases including PubMed, Embase, Cochrane, Web of Science, CNK...

Full description

Saved in:
Bibliographic Details
Main Authors: Haoyang Wang, Junying Pan, Mingming Zhang, Zengde Tan
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Pharmacology
Subjects:
Aβ monoclonal antibody
lecanemab
donanemab
alzheimer’s disease
clinical outcomes
adverse reactions
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1599048/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1599048/full

Similar Items